Literature DB >> 1981162

The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.

I Irwin1, L E DeLanney, L S Forno, K T Finnegan, D A Di Monte, J W Langston.   

Abstract

The MPTP-treated monkey has become an important model for the study of Parkinson's disease. However, studies on the acute evolution of the neurotoxic effects of MPTP in primates are lacking. In the present study, 17 squirrel monkeys were given a single subcutaneous injection of MPTP (2.5 mg/kg). The behavioral effects and the concentrations of dopamine (DA), dihydroxyphenylacetic acid and homovanillic acid were determined in caudate, putamen and substantia nigra 1, 3, 5 (n = 3/time point) and 10 days (n = 6) after drug administration. Two animals were studied neuropathologically 8 and 9 days after MPTP. Profound parkinsonism was evident in all animals after 1 day and neuropathological examination revealed severe nerve cell destruction in the substantia nigra. Surprisingly, although 50-75% reductions in nigral DA were observed 1 and 3 days after MPTP, caudate DA was not reduced and putaminal DA was increased at these time points. The temporal sequence of these events differs markedly from that which occurs in the MPTP-treated mouse and suggests that, in the monkey, nigral cell bodies may represent an important initial site of MPTP-induced damage. Five and 10 days after MPTP, nigral DA depletions remained greater than 60% of control and striatal DA was reduced 50-85%. At these time points, the putamen was always more affected than the caudate. This interregional pattern of striatal DA deficits is similar to that seen in idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981162     DOI: 10.1016/0006-8993(90)90780-f

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

Authors:  B J Snow; F J Vingerhoets; J W Langston; J W Tetrud; V Sossi; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

3.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

4.  Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.

Authors:  Samer D Tabbal; Linlin Tian; Morvarid Karimi; Christopher A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Exp Neurol       Date:  2012-07-24       Impact factor: 5.330

Review 5.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

6.  Evolution of nerve fiber degeneration in the striatum in the MPTP-treated squirrel monkey.

Authors:  L S Forno; L E DeLanney; I Irwin; J W Langston
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

Review 7.  Convergent evidence for abnormal striatal synaptic plasticity in dystonia.

Authors:  David A Peterson; Terrence J Sejnowski; Howard Poizner
Journal:  Neurobiol Dis       Date:  2009-12-18       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.